» Articles » PMID: 14732819

Iron Requirements in Hemodialysis

Overview
Journal Blood Purif
Specialty Hematology
Date 2004 Jan 21
PMID 14732819
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The correction of anemia in dialysis patients with erythropoietin (EPO) can be frustrated by insufficient iron. To address this effect, we preloaded candidate EPO patients with intravenous iron in the early 1990s. Preloading with 900-1,525 mg of iron yielded the following results: 70% of patients had increasing hematocrits (HCTs) without EPO, and 40% of patients had HCTs greater than 30%. Apparent lack of iron led to blood loss studies. Routes evaluated were blood sampling, dialyzer clotting, blood in the dialyzer circuit and postdialysis bleeding. Projected annual losses were between 2,516 and 5,126 ml, depending on circuit and posttreatment losses. In terms of red cell loss, the results are comparable to those in the early days of dialysis before the introduction of current technology. Extension of these studies to daily dialysis predicts possible losses with this 6 times a week therapy of between 4,663 and 9,884 ml per year.

Citing Articles

High Ferritin Is Not Needed in Hemodialysis Patients: A Retrospective Study of Total Body Iron and Oral Iron Replacement Therapy.

Ogawa C, Tsuchiya K, Tomosugi N, Maeda K Int J Mol Sci. 2024; 25(3).

PMID: 38338786 PMC: 10855056. DOI: 10.3390/ijms25031508.


Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.

Zhang L, Gan L, Li K, Xie P, Tan Y, Wei G Eur J Clin Pharmacol. 2022; 78(9):1421-1434.

PMID: 35711066 PMC: 9365747. DOI: 10.1007/s00228-022-03328-9.


A systemic review and meta-analysis on the efficacy and safety of ferumoxytol for anemia in chronic kidney disease patients.

Zuo Q, Wang T, Zhu L, Li X, Luo Q Ren Fail. 2022; 44(1):94-102.

PMID: 35156909 PMC: 8856040. DOI: 10.1080/0886022X.2021.2021237.


The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Lorentz C, Tucker E, Verbout N, Shatzel J, Olson S, Markway B Blood. 2021; 138(22):2173-2184.

PMID: 34086880 PMC: 8641100. DOI: 10.1182/blood.2021011725.


Application of Reticulocyte-Based Estimation of Red Blood Cell Lifespan in Anemia Management of End-Stage Renal Disease Patients.

Nguyen L, Meaney C, Rao G, Panesar M, Krzyzanski W AAPS J. 2020; 22(2):40.

PMID: 32016602 DOI: 10.1208/s12248-020-0424-9.